MedEngine

23/10/2025

💻 MedEngine Webinars: Real-World Evidence in the Nordics – Insights for Pharma

📅 Tuesday, Oct 28 at 12:00 CET

MedEngine’s Scientific Consultant Mirkka Koivusalo will dive into how Nordic healthcare data can be leveraged to generate meaningful real-world evidence for pharma. The session will highlight the opportunities and challenges unique to the region, followed by an open Q&A for discussion led by MedEngine CEO Tero Ylisaukko-oja.

🎥 By registering, you’ll also get access to a full webinar replay and Q&A session.

📲Read more: https://www.medengine.fi/news/medengine-webinars-real-world-evidence-in-the-nordics-insights-for-pharma/

✍️SIGN UP HERE: https://us06web.zoom.us/webinar/register/WN_4Y7bYM47Qi2AnUviEbzdKA

MedEngine’s Scientific Consultant Mirkka Koivusalo will dive into how Nordic healthcare data can be leveraged to generate meaningful real-world evidence for pharma.

21/10/2025

🎙️ Turning complex science into conversations people want to listen to takes more than just good questions!

MedEngine’s Digital Content Lead Klaus Elfving explains how we help experts share their insights through clear storytelling, professional audio, and tailored distribution that reaches the right audience.

Want to turn your expertise into engaging conversations? Let’s talk — message us or contact info@medengine.fi.

16/10/2025

🔬 InPress: Real-World Insights Into Generalized Pustular Psoriasis in Finland

Our new population-based study from , published in Skin Health and Disease, sheds light on characteristics of patients with generalized pustular psoriasis (GPP), a rare chronic and potentially life-threatening inflammatory skin disease. Using national registry data (1996–2021), we evaluated epidemiology, comorbidities, treatments, flare occurrence, risk factors for flares, and overall survival compared to matched population-based controls and controls with psoriasis vulgaris (PV).

🔍 Key findings:

⚫ GPP prevalence and incidence estimates were sensitive to criteria used in identification: prelavence decreased from 9.9 to 4.7 per 100,000, and incidence from 4.2 to 2.1 per 100,000 with stricter case criteria.
⚫ Several comorbidities evaluated were more common in GPP compared not only to population-based control group but also to PV.
⚫ Overall survival was significantly lower in patients with GPP versus controls.
⚫ 43% experienced flares during follow-up, of which one-third (33%) had a flare at the time of first GPP diagnosis.
⚫ Systemic corticosteroid use increased the risk of flares
⚫ Flares were associated with a higher risk of death.

💡 These findings underscore the high disease burden of GPP and shorter survival and highlight the urgent need for standardized guidelines to improve timely diagnosis and management.

📖 Read the full article here: https://doi.org/10.1093/skinhd/vzaf076

📚 Read more of our studies: https://www.medengine.fi/publications/

🤝 This study was a collaboration by researchers from , Boehringer Ingelheim, Tampere University Hospital, Helsinki University Central Hospital and Oulu University Hospital.

14/10/2025

📰 This past summer, our latest article in the FinWeight series sparked a nationwide conversation and made headlines across Finland. But what is the study really about, and why is it significant not only nationally but also globally?

In this article, MedEngine's Aino Vesikansa explores the background, findings, and global relevance of the FinWeight study, featuring insights from Professor Kirsi Pietilainen and Tero Saukkonen, Medical Director at Novo Nordisk, both closely involved in the research.

https://www.medengine.fi/news/the-finweight-study/

This past summer, our latest publication in the FinWeight series sparked a nationwide conversation and made headlines across Finland.

07/10/2025

💡 Understanding the real-world perspectives of healthcare stakeholders is essential for driving meaningful change.

At MedEngine, Senior Scientific Consultant Emmi Joensuu leads Real-World Insight projects, helping pharmaceutical companies identify the insights from different stakeholders – opinions, practices, and needs – that can’t be captured through traditional registry data.

“Real-World Insight means listening to stakeholders – such as doctors, nurses, and patients – and learning directly from their experiences,” Emmi explains. “Through interviews and surveys, we gain a deeper understanding of, for example, current treatment practices, awareness levels, and decision-making processes.”

These insights can, for example, shape market access strategies, support product launches, and guide the development of treatment practices.

“What I find most rewarding,” Emmi adds, “is seeing how these insights can be transformed into concrete actions, whether it’s developing strategy, creating meaningful communication materials, or improving healthcare practices.”

02/10/2025

💡 In our latest Nordic Insights blog, we explore why the Nordic countries—though small in size—play an outsized role in pharmaceutical commercialization. From early planning and evidence generation to local adaptation and real-world data, success in the region requires a truly tailored approach.

📲 Read the full article: https://www.medengine.fi/news/unlocking-the-nordics/

With world-class healthcare systems, openness to innovation, and unique opportunities for evidence generation, the Nordic offers a valuable platform for pharma companies. Read more on our blog article Unlocking the Nordics: Pharma Strategies That Deliver Impact.

30/09/2025

✨ Engaging healthcare professionals today requires more than just presence across channels. It’s about delivering the right content at the right moment, in a way that feels seamless and valuable. MedEngine’s Scientific Consultant Laura Mäntylä helps clients build integrated communication strategies that truly put the customer experience at the center.

“Omnichannel means creating connected experiences, so that every message, channel, and interaction supports the next,” Laura explains. “The goal is to make communication feel effortless, relevant, and valuable for healthcare professionals.”

With her background in scientific communication, Laura bridges data-driven insights with creative ex*****on. She thrives on helping clients move from isolated campaigns to connected journeys. “When content and channels are coordinated, every interaction builds on the last, and that’s when engagement becomes both efficient and meaningful.”

📲 https://www.medengine.fi/

25/09/2025

🇩🇰🇸🇪🇫🇮🇳🇴 Making Nordic research succeed takes more than just crossing borders!

MedEngine’s Project Manager Sofie Damgaard shares her insights: experienced local teams in all four Nordic countries, deep knowledge of data sources and regulations, and trusted collaboration with both regulators and clinical experts. It’s about building strong partnerships that make complex research run smoothly across the region.

Curious about how we keep research operations seamless? Let’s talk—message us or contact info@medengine.fi

23/09/2025

For MedEngine’s Senior Consultant Kalle Aaltonen, pricing and reimbursement is far more than a regulatory formality. It’s the key process that ensures patients can benefit from safe and effective new therapies.

With more than seven years of experience at the Pharmaceuticals Pricing Board, Kalle understands every fine detail of what it takes to be granted price and reimbursement in Finland.

“At MedEngine we take a holistic view on market access,” Kalle explains. “In addition to the required technical elements, we understand the data and potential data gaps, evaluate commercial potential and launch strategies. It is also essential to be able to combine market access expertise with evidence generation capabilities.”

For Kalle, the true reward lies in the impact on patients: “It is always very rewarding to help patients access the latest innovations that are not only effective and safe, but also cost-effective.”

18/09/2025

The MedEngine Mid-Year Meeting 2025 brought us together to reflect on the year so far.

Between updates and workshops, we also made time for laughter, good food, and a little sunshine. And nature! We even spotted moose and deer. 🦌🌲

Events like these remind us why we love what we do — and who we do it with. Here’s a moment from the year where we stepped away from the day-to-day and looked ahead, together.

16/09/2025

We’re excited to join the Nordic Rare Disease Summit 2025, starting today in Copenhagen! 🌍✨

Individually rare, but collectively affecting over one million people across the Nordics, rare diseases require collaboration across patients, associations, academia, policymakers, and industry. Over the next two days, the summit will focus on:

✔️ Improving policies and quality of life for those living with rare diseases
✔️ Sharing best practices and scalable solutions
✔️ Recognising lived experience as a vital resource

Representing MedEngine:
👤 Saku Torvinen, PhD
👤 Tero Ylisaukko-oja

We look forward to meaningful discussions, new connections, and building better solutions together. If you’re attending, come say hello!

11/09/2025

💼 For MedEngine’s Scientific Project Manager Katariina Kiviaho, successful market access begins with a clear understanding of the landscape. A strong strategy must be grounded in up-to-date local data and deep analysis.

"In our Landscape Mapping projects, we go beyond the surface, combining epidemiology and disease burden insights with product positioning, and identifying unmet needs and data gaps,” Katariina explains. “Our analyses draw on both expert interviews and comprehensive desktop research.”

It’s equally important to analyze the competitor landscape and the broader international context, extracting key learnings that can be applied to strengthen the local market access strategy.

For Katariina, the most meaningful part is building this essential foundation: “Collecting and analyzing data that forms the basis of the access strategy is highly rewarding. This is the groundwork that truly helps our clients.”

📲 https://www.medengine.fi/